vs
安捷伦科技（A）与NATIONAL HEALTHCARE CORP（NHC）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是NATIONAL HEALTHCARE CORP的4.7倍（$1.8B vs $386.5M）。安捷伦科技净利率更高（17.0% vs 6.4%，领先10.5%）。安捷伦科技同比增速更快（7.0% vs 4.6%）。安捷伦科技自由现金流更多（$175.0M vs $6.4M）。过去两年NATIONAL HEALTHCARE CORP的营收复合增速更高（14.0% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
HCA Healthcare是1968年成立的美国营利性医疗服务运营商，总部位于田纳西州纳什维尔。截至2020年5月，该公司在全美20个州及英国持有并运营186家医院，还有约2400个医疗服务网点，涵盖手术中心、独立急诊室、紧急护理中心及医师诊所，2024年位列美国财富500强第61位。
A vs NHC — 直观对比
营收规模更大
A
是对方的4.7倍
$386.5M
营收增速更快
A
高出2.3%
4.6%
净利率更高
A
高出10.5%
6.4%
自由现金流更多
A
多$168.6M
$6.4M
两年增速更快
NHC
近两年复合增速
6.9%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $386.5M |
| 净利润 | $305.0M | $24.8M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 8.6% |
| 净利率 | 17.0% | 6.4% |
| 营收同比 | 7.0% | 4.6% |
| 净利润同比 | -4.1% | 308.6% |
| 每股收益（稀释后） | $1.07 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $386.5M | ||
| Q3 25 | $1.7B | $382.7M | ||
| Q2 25 | $1.7B | $374.9M | ||
| Q1 25 | $1.7B | $373.7M | ||
| Q4 24 | $1.7B | $369.4M | ||
| Q3 24 | $1.6B | $340.2M | ||
| Q2 24 | $1.6B | $300.7M |
净利润ANHC
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $24.8M | ||
| Q3 25 | $336.0M | $39.2M | ||
| Q2 25 | $215.0M | $23.7M | ||
| Q1 25 | $318.0M | $32.2M | ||
| Q4 24 | $351.0M | $6.1M | ||
| Q3 24 | $282.0M | $42.8M | ||
| Q2 24 | $308.0M | $26.8M |
毛利率ANHC
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率ANHC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 8.6% | ||
| Q3 25 | 20.7% | 7.9% | ||
| Q2 25 | 18.0% | 9.1% | ||
| Q1 25 | 22.4% | 8.2% | ||
| Q4 24 | 24.0% | 7.8% | ||
| Q3 24 | 21.1% | 6.7% | ||
| Q2 24 | 23.1% | 7.5% |
净利率ANHC
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 6.4% | ||
| Q3 25 | 19.3% | 10.3% | ||
| Q2 25 | 12.9% | 6.3% | ||
| Q1 25 | 18.9% | 8.6% | ||
| Q4 24 | 20.6% | 1.6% | ||
| Q3 24 | 17.9% | 12.6% | ||
| Q2 24 | 19.6% | 8.9% |
每股收益（稀释后）ANHC
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.58 | ||
| Q3 25 | $1.18 | $2.50 | ||
| Q2 25 | $0.75 | $1.52 | ||
| Q1 25 | $1.11 | $2.07 | ||
| Q4 24 | $1.23 | $0.38 | ||
| Q3 24 | $0.97 | $2.73 | ||
| Q2 24 | $1.05 | $1.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $92.8M |
| 总债务越低越好 | $3.0B | $40.0M |
| 股东权益账面价值 | $6.9B | $1.1B |
| 总资产 | $12.8B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资ANHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $92.8M | ||
| Q3 25 | $1.5B | $130.6M | ||
| Q2 25 | $1.5B | $111.0M | ||
| Q1 25 | $1.5B | $90.4M | ||
| Q4 24 | $1.3B | $76.1M | ||
| Q3 24 | $1.8B | $84.8M | ||
| Q2 24 | $1.7B | $136.2M |
总债务ANHC
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $40.0M | ||
| Q3 25 | $3.4B | $73.1M | ||
| Q2 25 | $3.3B | $110.0M | ||
| Q1 25 | $3.3B | $134.0M | ||
| Q4 24 | $3.3B | $137.0M | ||
| Q3 24 | $2.1B | $147.0M | ||
| Q2 24 | $2.1B | — |
股东权益ANHC
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.1B | ||
| Q3 25 | $6.4B | $1.1B | ||
| Q2 25 | $6.1B | $1.0B | ||
| Q1 25 | $6.0B | $1.0B | ||
| Q4 24 | $5.9B | $980.2M | ||
| Q3 24 | $5.9B | $983.5M | ||
| Q2 24 | $6.2B | $945.8M |
总资产ANHC
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $1.5B | ||
| Q3 25 | $12.2B | $1.6B | ||
| Q2 25 | $12.2B | $1.6B | ||
| Q1 25 | $11.9B | $1.5B | ||
| Q4 24 | $11.8B | $1.5B | ||
| Q3 24 | $11.0B | $1.6B | ||
| Q2 24 | $10.9B | $1.3B |
负债/权益比ANHC
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.04× | ||
| Q3 25 | 0.53× | 0.07× | ||
| Q2 25 | 0.55× | 0.11× | ||
| Q1 25 | 0.56× | 0.13× | ||
| Q4 24 | 0.57× | 0.14× | ||
| Q3 24 | 0.36× | 0.15× | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $16.8M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $6.4M |
| 自由现金流率自由现金流/营收 | 9.7% | 1.7% |
| 资本支出强度资本支出/营收 | 5.2% | 2.7% |
| 现金转化率经营现金流/净利润 | 0.88× | 0.68× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $148.6M |
8季度趋势，按日历期对齐
经营现金流ANHC
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $16.8M | ||
| Q3 25 | $362.0M | $66.2M | ||
| Q2 25 | $221.0M | $62.8M | ||
| Q1 25 | $431.0M | $39.3M | ||
| Q4 24 | $481.0M | $12.8M | ||
| Q3 24 | $452.0M | $34.2M | ||
| Q2 24 | $333.0M | $50.7M |
自由现金流ANHC
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $6.4M | ||
| Q3 25 | $259.0M | $56.5M | ||
| Q2 25 | $107.0M | $52.6M | ||
| Q1 25 | $334.0M | $33.1M | ||
| Q4 24 | $388.0M | $4.6M | ||
| Q3 24 | $360.0M | $28.6M | ||
| Q2 24 | $230.0M | $42.8M |
自由现金流率ANHC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 1.7% | ||
| Q3 25 | 14.9% | 14.8% | ||
| Q2 25 | 6.4% | 14.0% | ||
| Q1 25 | 19.9% | 8.9% | ||
| Q4 24 | 22.8% | 1.3% | ||
| Q3 24 | 22.8% | 8.4% | ||
| Q2 24 | 14.6% | 14.2% |
资本支出强度ANHC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 2.7% | ||
| Q3 25 | 5.9% | 2.5% | ||
| Q2 25 | 6.8% | 2.7% | ||
| Q1 25 | 5.8% | 1.6% | ||
| Q4 24 | 5.5% | 2.2% | ||
| Q3 24 | 5.8% | 1.7% | ||
| Q2 24 | 6.5% | 2.6% |
现金转化率ANHC
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 0.68× | ||
| Q3 25 | 1.08× | 1.69× | ||
| Q2 25 | 1.03× | 2.65× | ||
| Q1 25 | 1.36× | 1.22× | ||
| Q4 24 | 1.37× | 2.10× | ||
| Q3 24 | 1.60× | 0.80× | ||
| Q2 24 | 1.08× | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
NHC
| Inpatient Services Segment | $333.7M | 86% |
| Homecare Services Segment | $40.0M | 10% |
| Other | $11.2M | 3% |
| National | $1.6M | 0% |
